



CA-ADAP Formulary Review: Human Respiratory Syncytial Virus (RSV)

SEPTEMBER 2023

CARRIE HOLDEN, PHARM.D

MagellanRx
MANAGEMENTSM

CA-ADAP Formulary Review: AGENDA


① Disease Characteristics

② Medications

③ Claims data

④ Other ADAP formularies

⑤ Discussion




RESPIRATORY SYNCYTIAL VIRUS (RSV)

Respiratory Syncytial Virus (RSV)



- Most common virus to infect children
- Highly contagious
- Seasonal (winter)
- Causes obstruction to the normal airways
- Typically presents as upper respiratory infection (cold-like symptoms)
- Can cause bronchiolitis, lower respiratory tract illness w/small airway obstruction, pneumonia, respiratory failure, apnea, death
- Premature infants, elderly, pre-existing heart, lung, neurologic, and immunosuppressive disorders affected more severely



RSV cont'd



- Frequent reinfection
- Spread from person to person via respiratory droplets
- Upper-respiratory tract:
 - Rhinorrhea
 - Nasal congestion
 - Cough
 - Sneezing
 - Fever/myalgia
- Lower-respiratory tract:
 - Rhonchorous breath sounds
 - Fast breathing (tachypnea)
 - Wheezing
 - Prolonged expiration



RSV Treatment: RIBIVIRIN



- *Efficacy data for treatment of RSV in adults is limited to use in immunocompromised patients, particularly HSCT recipients.*

Agent	Generic	UNIQUE Claims AUG 2022 – AUG 2023	AZ	CT	FL	NY	TX	WA	Comments
RIBIVIRIN (AEROSOLIZED)	Y	<i>0 Rejected</i>	-	-	-	-	-	-	<ul style="list-style-type: none"> • <i>Continuous given over 12-18 hrs/day for 3-7 days</i> • <i>Intermittent given over 2-4 hrs every 8 hrs for 3-7 days</i>
RIBIVIRIN (ORAL)	Y	<i>0 Paid</i>	Y	Y	Y	Y	-	Y	<ul style="list-style-type: none"> • <i>Weight-based; optimal dosing has not been established</i>


RSV Infection Prophylaxis



- Nirsevimab and Palivizumab: for infants and neonates
- RSV Vaccine: For RSV infection prophylaxis for the prevention of lower respiratory tract disease (LRTD)

Agent	Generic	Denials AUG 2022 – AUG 2023	AZ	CT	FL	NY	TX	WA	Comments
<i>AREXVY</i>	N	4	-	-	-	-	-	-	
<i>ABRYSVO</i>	N	3	-	-	-	-	-	-	

Formulary Management Recommendations: RSV Treatment and Prophylaxis



1

Treatment:
Ribavirin

Oral tablet on CA-ADAP Formulary; do not recommend addition of aerosolized

2

Prophylaxis:
RSV Vaccine

Consider addition to the CA-ADAP formulary

References



- Cohen, J. (2020) *Why do dozens of diseases wax and wane with the seasons—and ... - science*, *Science.org*. Available at: <https://www.science.org/content/article/why-do-dozens-diseases-wax-and-wane-seasons-and-will-covid-19> (Accessed: 26 September 2023). (photo only)
- *Frequently asked questions about RSV vaccine for adults (2023)* Centers for Disease Control and Prevention. Available at: <https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults-faqs.html> (Accessed: 26 September 2023).
- Hanish, J., Schweitzer, J.W. and Justice, N.A. (2023) *Respiratory syncytial virus infection - NCBI bookshelf, National Library of Medicine*. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK459215/> (Accessed: 25 September 2023).
- *Respiratory syncytial virus (RSV) (2023)* Mayo Clinic. Available at: <https://www.mayoclinic.org/diseases-conditions/respiratory-syncytial-virus/symptoms-causes/syc-20353098> (Accessed: 25 September 2023).

Confidentiality statement



By receipt of this presentation, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, or distributed to or disclosed to others at any time without the prior written consent of Magellan Health, Inc.

The information contained in this presentation is intended for educational purposes only and is not intended to define a standard of care or exclusive course of treatment, nor be a substitute for treatment.

The information contained in this presentation is intended for educational purposes only and should not be considered legal advice. Recipients are encouraged to obtain legal guidance from their own legal advisors.